Oncology News | pharmaphorum

News

Keytruda breaks new ground in cervical cancer

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/

News

Study finds hundreds of overlooked cancer drug targets

Researchers from the Wellcome Sanger Institute and partners have carried out a comprehensive analysis of cancer cells, identifying 370 ‘priority’ targets that could be use

News

FDA starts review of Lantheus’ generic Lutathera

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tu

News

UK study backs whole-genome screening for cancer care

A major new study in the UK has shown that combining whole-genome sequencing (WGS) and real-world clinical data at a national scale can help deliver tailored, personalised

News

FDA blocks Astellas’ Claudin cancer drug over manufacturing

Manufacturing problems have scuppered Astellas’ chances of approval in the US this month for zolbetuximab, currently leading the field among Claudin 18.2-targeted drug can

News

JPM kicks off with takeovers by J&J, Novartis, and MSD

The slew of news from the JP Morgan Healthcare conference that started this morning started with a trio of takeover deals from Johnson & Johnson, Novartis, and MSD.

Keytruda breaks new ground in cervical cancer

Study finds hundreds of overlooked cancer drug targets

FDA starts review of Lantheus’ generic Lutathera

UK study backs whole-genome screening for cancer care

FDA blocks Astellas’ Claudin cancer drug over manufacturing

JPM kicks off with takeovers by J&J, Novartis, and MSD

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks